+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • ID: 5353561
  • Report
  • May 2021
  • Region: Global
  • 90 pages
  • Acute Market Reports

FEATURED COMPANIES

  • Bayer AG
  • Bristol-Myers Squibb.
  • F. HOFFMAN LA ROCHE
  • Genentech Inc.
  • Novo Nordisk
  • Sanofi
  • MORE
The Acquired Hemophilia Treatment Market is anticipated to grow at a compound annual growth rate of 3.3% for the forecast period of 2021 to 2029. This growth is mainly fueled by rising rate of prophylaxis treatment among patients. This report covers all the quantitative and qualitative aspects of the Acquired Hemophilia Market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.


Acquired Hemophilia Treatment Market: Overview

Acquired Hemophilia (AH) is a rare auto-immune bleeding condition that severely impairs the body's capacity to form a clot during the event of a hemorrhage that arises in people with no family history of diseases related to clotting or coagulation. The body produces inhibitors (antibodies) that target clotting factors, most commonly factor VIII, in Acquired Hemophilia. Clotting factors are specialized proteins that are needed for normal blood clotting. Eventually, affected people develop disorders related to severe bleeding into the muscles, skin and soft tissues. AH, at times is also related to medical conditions such as cancer, tumors and pregnancy other than rheumatoid arthritis, ulcerative colitis, and psoriasis.

The market has been categorized and sub-categorized on basis of Type, Treatment, Therapeutic Areas, End Users and Regional Basis. While viewing this market on the basis of Type, Hemophilia A presides the market share by 50%-60% and is the most severe type whereas Hemophilia B only constitutes 20% of the market share.

Increasing Prevalence of AH among New Born Demands Effective Treatment

The key compelling factors of this market are increasing prevalence of Acquired Hemophilia in newborn, rising diagnostic rates, Increase in use of Prophylactic treatment, rising awareness among people, rising number of auto-immune diseases and beneficial reimbursement policies. Generally, AH is found in old age population and has a mortality rate of 21%, if not treated. Hemophilia A, is the most severe and commonly found type of Acquired Hemophilia. The challenges faced by AH Treatment Market are: high cost of treatment hindering penetration in low and middle income countries, lack of availability and accessibility of new drugs and adoption rate of technologically advanced products is low.

Healthcare Infrastructure in NA Offers Effective Access to Therapeutic Options

On the basis of regional segmentation, Acquired Hemophilia Treatment Market includes North America, Latin America, Europe, Asia Pacific, Middle East and Africa, and Rest of the World. North America dominates the AH Treatment Market in 2020. The key drivers of this market in North America have been U.S. people getting diagnosed at young age, growing awareness among people, better medical health facilities, the favorable reimbursement scenario for medicines prescribed for the treatment of acquired hemophilia further strengthens the region's market development. The European Medical Agency (EMA) created a supportive regulatory climate by authorizing FastTrack classification for drug discovery and production of medicines for treating acquired hemophilia, putting Europe in second place. Key Players ruling this market are: Baxter Healthcare Corporation, Biogen, Sanofi, Shire (Baxalta), CSL Behring, Pfizer, Inc., Bayer AG, Ferring Pharmaceuticals, Spark Therapeutics Inc., F. HOFFMAN LA ROCHE, Sanofi, Genentech, Inc., Novo Nordisk, GlaxoSmithKline Plc, and Bristol-Myers Squibb. Industry leaders are targeting on developing Research and Development activities, new product launches.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.

Report Scope by Segments

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Bristol-Myers Squibb.
  • F. HOFFMAN LA ROCHE
  • Genentech Inc.
  • Novo Nordisk
  • Sanofi
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2.Research Scope
1.3.Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2.Bottom-Up Approach
1.3.5.Assumptions
1.3.7. Market Segmentation

Chapter 2. Executive Summary
2.1. Acquired Hemophilia Treatment Market Portraiture
2.2. Acquired Hemophilia Treatment Market, by type, 2020 (US$ Mn)
2.3. Acquired Hemophilia Treatment Market, by treatment, 2020 (US$ Mn)
2.4. Acquired Hemophilia Treatment Market, by type of therapeutic area, 2020 (US$ Mn)
2.5. Acquired Hemophilia Treatment Market, by type of end user, 2020 (US$ Mn)
2.6. Acquired Hemophilia Treatment Market, by Geography, 2020 (Value)
2.7. Impact of Covid - 19

Chapter 3. Acquired Hemophilia Treatment Market: Market Dynamics and Future Outlook
3.1.Market Overview
3.2. Current Scenario: New Product Launches, Increase in Animal Free Testing
3.3. Drivers
3.3.1. Increasing prevalence of Hemophilia in neonatal population
3.3.2. Rising testing rates
3.3.3 Prophylactic treatment used more often
3.4. Challenges
3.4.1. High Cost of Treatment
3.4.2. Lack of Knowledge
3.5. Opportunities
3.7. Attractive Investment Proposition, by Geography, 2020
3.7. Competitive Landscape (Key Players)
3.7.1. Mergers and Acquisition Analysis
3.7.2. Agreements, Collaborations and Partnership
3.7.3. New Product Launches

Chapter 4. Acquired Hemophilia Treatment Market, By Type, 2019 – 2029 (US$ Mn)
4.1. Overview
4.2. Hemophilia A
4.3. Hemophilia B
4.4. Hemophilia C
4.5. Others

Chapter 5. Acquired Hemophilia Treatment Market, By Treatment, 2019 – 2029 (US$ Mn)
5.1. Overview
5.2. On-Demand
5.3. Prophylaxis

Chapter 6. Acquired Hemophilia Treatment Market, By Therapeutic Areas, 2019 – 2029 (US$ Mn)
6.1. Overview
6.2. Replacement Therapy
6.3. Gene Therapy
6.4. Immune Tolerance Induction Therapy
6.5. Others

Chapter 7. Acquired Hemophilia Treatment Market, By Type of End User, 2019 – 2029 (US$ Mn)
7.1. Overview
7.2. Hospitals
7.3. Clinics
7.4. Others

Chapter 8. Acquired Hemophilia Treatment, By Regional Market Analysis, 2019 – 2029 (US$ Mn)
8.1. Definition & Scope
8.2. Regional Market Share Analysis, 2019& 2029
8.3. Regional Market Dashboard
8.4. Regional Market Snapshot
8.5. Regional Market Share Analysis 2019 to 2029
8.5.1. North America
8.5.2. Europe
8.5.3. Asia Pacific
8.5.4. Latin America
8.5.5. Middle East and Africa
8.6. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.6.1. North America
8.6.2. Europe
8.6.3. Asia Pacific
8.6.4. Latin America
8.6.5. Middle East and Africa
8.7. Market Size, & Forecasts, Revenue and Trend Analysis, 2019 to 2029

Chapter 9. North America Acquired Hemophilia Treatment, Regional Market Analysis, 2019 – 2029 (US$ Mn)
9.1. North America Acquired Hemophilia Treatment Market Analysis, 2019-2029
9.2. North America Acquired Hemophilia Treatment Market, by type, 2019 – 2029 (US$ Mn)
9.3. North America Acquired Hemophilia Treatment Market, by treatment, 2019 – 2029 (US$ Mn)
9.4. North America Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 – 2029 (US$ Mn)
9.5. North America Acquired Hemophilia Treatment Market, by end user, 2019 – 2029 (US$ Mn)
9.6. North America Acquired Hemophilia Treatment Market, by region, 2019 – 2029 (US$ Mn)
9.6.1. U.S.
9.6.2. Canada

Chapter 10. Latin America Acquired Hemophilia Treatment, Regional Market Analysis, 2019 – 2029 (US$ Mn)
10.1. Latin America Acquired Hemophilia Treatment Market Analysis, 2019-2029
10.2. Latin America Acquired Hemophilia Treatment Market, by type, 2019 – 2029 (US$ Mn)
10.3. Latin America Acquired Hemophilia Treatment Market, by treatment, 2019 – 2029 (US$ Mn)
10.4. Latin America Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 – 2029 (US$ Mn)
10.5. Latin America Acquired Hemophilia Treatment Market, by end user, 2019 – 2029 (US$ Mn)
10.6. Latin America Acquired Hemophilia Treatment Market, by region, 2019 – 2029 (US$ Mn)
10.6.1. Brazil
10.6.2. Argentina
10.6.3. Mexico

Chapter 11. Europe Acquired Hemophilia Treatment, Regional Market Analysis, 2019 – 2029 (US$ Mn)
11.1. Europe Acquired Hemophilia Treatment Market Analysis, 2019-2029
11.2. Europe Acquired Hemophilia Treatment Market, by type, 2019 – 2029 (US$ Mn)
11.3. Europe Acquired Hemophilia Treatment Market, by treatment, 2019 – 2029 (US$ Mn)
11.4. Europe Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 – 2029 (US$ Mn)
11.5. Europe Acquired Hemophilia Treatment Market, by end-user, 2019 – 2029 (US$ Mn)
11.6. Europe Acquired Hemophilia Treatment Market, by region, 2019 – 2029 (US$ Mn)
11.6.1. United Kingdom
11.6.2. Germany
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe

Chapter 12. Asia Pacific Acquired Hemophilia Treatment, Regional Market Analysis, 2019 – 2029 (US$ Mn)
12.1. Asia Pacific Acquired Hemophilia Treatment Market Analysis, 2019-2029
12.2. Asia Pacific Acquired Hemophilia Treatment Market, by type, 2019 – 2029 (US$ Mn)
12.3. Asia Pacific Acquired Hemophilia Treatment Market, by treatment, 2019 – 2029 (US$ Mn)
12.4. Asia Pacific Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 – 2029 (US$ Mn)
12.5. Asia Pacific Acquired Hemophilia Treatment Market, by end-user, 2019 – 2029 (US$ Mn)
12.6. Asia Pacific Acquired Hemophilia Treatment Market, by region, 2019 – 2029 (US$ Mn)
12.6.1. Japan
12.6.2. China
12.6.3. India
12.6.4. ASEAN
12.6.5. Rest of APAC

Chapter 13. Middle East & Africa (MEA)Acquired Hemophilia Treatment, Regional Market Analysis, 2019 – 2029 (US$ Mn)
13.1. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market Analysis, 2019 – 2029
13.2. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by type, 2019 – 2029 (US$ Mn)
13.3. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by treatment, 2019 – 2029 (US$ Mn)
13.4. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 – 2029 (US$ Mn)
13.5. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by end-user, 2019 – 2029 (US$ Mn)
13.6. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by region, 2019 – 2029 (US$ Mn)
13.6.1. Saudi Arabia
13.6.2. United Arab Emirates
13.6.3. South Africa
13.6.4. Rest of MEA

Chapter 14. Company Profiles
14.1. Baxter Healthcare Corporation
14.2. Biogen
14.3. Pfizer
14.4. F. HOFFMAN LA ROCHE
14.5. Sanofi
14.6. Ferring Pharmaceuticals
14.7. Genentech, Inc.
14.8. Bristol-Myers Squibb
14.9. Novo Nordisk
14.10. GlaxoSmithKline, Plc
14.11.Shire (Baxalta)
14.12.CSL Behring
14.13.Bayer AG
14.14.Spark Therapeutics Inc.
Note: Product cover images may vary from those shown
  • Baxter Healthcare Corporation
  • Biogen
  • Sanofi
  • Shire (Baxalta)
  • CSL Behring
  • Pfizer Inc.
  • Bayer AG
  • Ferring Pharmaceuticals
  • Spark Therapeutics Inc.
  • F. HOFFMAN LA ROCHE
  • Sanofi
  • Genentech Inc.
  • Novo Nordisk
  • GlaxoSmithKline Plc
  • Bristol-Myers Squibb.
Note: Product cover images may vary from those shown
Adroll
adroll